Kornimate/medical-research-clean huggingface dataset:
efficacy of stellate ganglion block in patients with parkinson's disease

Conditions: Parkinson Disease

Summary: the goal of this or clinical trial is to explore efficacy of stellate ganglion block on dysphagia and activities of daily living in patients with parkinson's disease. the main question it aims to answer are: • can stellate ganglion block improve the dysphagia and activities of daily living in patients with parkinson's disease. participants will be divided into the the control group and observation group evenly. all the patients were provided with routine therapy, while the patients in the observation group were given stellate ganglion block. the swallowing function, and activities of daily living of the two groups of patients before and after treatment were evaluated.

dysphagia, or swallowing difficulty, is a common symptom associated with parkinson's disease. it is characterized by weakened chewing and throat muscles, leading to difficulties in eating, coughing, and a sensation of choking in individuals with parkinson's disease. the goal of this or clinical trial is to explore efficacy of stellate ganglion block on dysphagia and activities of daily living in patients with parkinson's disease. the main question it aims to answer are: • can stellate ganglion block improve the dysphagia and activities of daily living in patients with parkinson's disease. participants will be divided into the the control group and observation group evenly. all the patients were provided with routine therapy, while the patients in the observation group were given stellate ganglion block. the swallowing function, and activities of daily living of the two groups of patients before and after treatment were evaluated.

Eligibility criteria:
inclusion criteria: * age \>18 years. * meeting the diagnostic criteria for parkinson's disease developed by the neurology branch of the chinese medical association in 2006. * diagnosed with dysphagia confirmed by the video fluoroscopic swallowing study. * stable vital signs, conscious, able to cooperate with assessment and treatment. exclusion criteria: * dysphagia possibly caused by other reasons, such as cerebrovascular disease, trauma, neuromuscular diseases, malignant diseases of the pharynx and larynx, and digestive tract diseases. * history of mental diseases or use of antipsychotics. * complicated with cognitive impairment or consciousness dysfunction. * simultaneously suffering from severe liver, kidney failure, tumors, or hematological diseases.
method of exit site care in chronic peritoneal dialysis patients

Conditions: Chronic Peritoneal Dialysis

Summary: peritoneal dialysis accounts for more than 70% of the dialysis modality in hong kong. exit site infection (esi) is one of the causes leading to peritoneal catheter removal. appropriate exit-site care can prevent esi. as the presence of a causative organism is essential in esi, eliminating organism invasion may be useful in preventing esi. in the present study, an exit site care method aiming at preventing organism invasion is developed to investigate its effectiveness in reducing esi. it is also hoped the present study can help to develop an exit site care method that can reduce the frequency of exit site dressing so as to reduce the burden of patients and to improve their quality of life. we'll recruit one hundred new chronic peritoneal dialysis patients into the study. the patients will be divided into two groups. one group of the patients will use film-dressing method (f) and the other group will use simple gauze dressing method (g). f group patients will have the exit site covered with a dressing film and keep it intact for 7 days after having the exit site cleaned with antiseptic solution. g group patients will clean the exit site with antiseptic solution and change the simple gauze dressing daily. the outcomes of the two groups will be compared. the outcome will be expressed in terms of exit site infection free period, peritonitis free period and exit site condition classification. patient subjective quality of life will also be compared at first and twelfth month.


Eligibility criteria:
inclusion criteria: * chronic renal failure patients with peritoneal catheter newly inserted exclusion criteria: * patients have exit-site infection before stitches removal or presence of signs and symptoms of exit-site infection at the time of remove stitches. * patients plan to move out of pwh or transplant soon after catheter insertion. * patients have known history of allergy to adhesives / tapes. * extremely non-compliant patients.

Keywords: renal failure infection peritonitis
visual function and patient satisfaction in glaucoma or ocular hypertensive patients undergoing simultaneous cataract surgery and i-stent implantation

Conditions: Lenses, Intraocular; Glaucoma Filtration Implants

Summary: new extended depth of focus intraocular lenses (iols) are being used in a broader spectrum of patients than trifocal iols. the purpose of this study is to evaluate visual improvement after cataract surgery in patients with glaucoma or ocular hypertension undergoing simultaneous cataract surgery with i-stent implantation with the implantation of a vivity iol. results will be compared with a group of glaucoma or ocular hypertension undergoing isolated cataract surgery with vivity implantation, as well as with patients with no pathology undergoing cataract surgery and vivity implantation

the purpose of this study is to report in detail visual function and patient satisfaction, as well as the need for spectacle correction, in patients with glaucoma and ocular hypertension undergoing cataract surgery with bilateral implantation of an extended depth of focus iol, the vivity iol. the study also seeks to determine if there are differences in the speed of visual improvement between patients undergoing isolated cataract surgery and patients undergoing simultaneous i-stent implantation. results will also be compared with a group of patients with no ocular pathology undergoing cataract surgery with vivity implantation. patients will be asked to join the study once the type of surgery (isolated phacoemulsification versus phacoemulsification combined with i-stent implantation) and the type of lens to be implanted (monofocal, edof, trifocal) has been agreed between ophthalmologist and patient. therefore, inclusion in the study will have no influence on surgical indication. once informed consent has been signed, the patient will be included in the study. explorations specific for the study will be performed 3 and 12 months after surgery and include: defocus curves contrast sensitivity self-reported photic phenomena need for spectacle correction satisfaction measured with the catquest sf9 questionnaire besides study-specific procedures, the following explorations which are standard of care will be performed one day, one week and one month after surgery: uncorrected binocular visual acuity for distance, intermediate and near distances monocular distance corrected and uncorrected visual acuity residual subjective refraction slit-lamp examination intraocular pressure and number of hypotensive drugs required description of any intra- or postsurgical complications

Eligibility criteria:
inclusion criteria: bilateral cataract surgery with vivity implantation with or without i_stent implantation exclusion criteria: ocular disease other than glaucoma
the effectiveness of lifestyle intervention on body composition, physical performances and quality of life among elderly people in long-term care facilities

Conditions: Sarcopenia; Obesity

Summary: purpose: to understand the change in body composition, physical functions and quality of life of elderly residents with sarcopenic obesity in ltc facilities after the implementation of exercise intervention.


Eligibility criteria:
inclusion criteria: 1. aged and elderly over 60 years old and no exercise restrictions. 2. conscious clear, able to communicate with to the traditional chinese language or taiwanese. 3. in the past three months living in long-term care institutions. 4. in the last month the subject biased static life 5. in a stable condition with enough energy: to maintain the support of at least one hour sitting in a wheelchair or bed edge. exclusion criteria: 1. in the past three months have unstable weight (\> ± 4 kg). 2. severe disease states, such as severe heart and lung liver and kidney disease, a serious cancer, severe malnutrition (mini nutritional assessment scale 0-7 points). 3. limb unable to anti-gravity completely 4. severe dementia (clinical dementia rating (cdr) scale clinical dementia rating, cdr 3-5 points).

Keywords: sarcopenic obesity body composition physical function quality of life long term care
ultraviolet exposure, antioxidant use and skin erythema at extreme high altitude

Conditions: Altitude; Ultraviolet Rays; Antioxidants; Oxidative Stress; Erythema

Summary: with the increasing tourism and adventure travel into extreme environments comes the need to reassess the required protection against ultraviolet (uv) radiation and possible other oxidative stresses. this is an observational study of uv radiation exposure and skin erythema while at extreme altitude (mt. everest). in addition to uv exposure, skin erythema, antioxidant use (such as vitamins c and e) will be measured. hypothesis: 1. uv radiation at extreme altitude has larger effects on the skin than at sea level; therefore requiring an adjustment of the antioxidant use for adequate protection. 2. the skin is an accurate reflection of uv and oxidative stress exposure 3. the efficacy of oxidatives stress is reflective of the ethnicity of the individual.

the literature widely acknowledges the deleterious effects of uv radiation on skin health, via production of oxidative free radicals. consequently, there have been numerous studies on the potential dermatological/anti-carcinogenic benefits of anti-oxidants, such as vitamins c and e, melatonin, green tea, zinc, and selenium. there is, however, a limited amount of literature on the quantity of uv exposure in high-risk settings, such as extreme altitude and equatorial zones. currently, there is no literature on uv exposure on mount everest. additionally, the efficacy of antioxidants (topical or systemic) has not yet been established in this environment. this will be an observational study where the principal investigator will collect accumulated ultraviolet exposure at different extreme altitudes during a 6 week period of a summit expedition on the north side of mt. everest. included in the data collection will be patient demographics, time, altitude, temperature, use of anti-oxidants, sunscreen (weighed), and skin erythema (spectophotometer).

Eligibility criteria:
inclusion criteria: * participants part of the expedition who are willing to wear the monitor, and disclose information of diet/antioxidant supplements and topical sunblock. exclusion criteria: * participants who are unwilling to carry the uv monitor or disclose their demographics

Keywords: environmental medicine altitude ultraviolet rays antioxidants oxidative stress erythema
light vs. moderate intensity exercise in individuals with myasthenia gravis

Conditions: Myasthenia Gravis

Summary: the overall purpose of this pilot study is to examine the feasibility, acceptability, and tolerability of light and moderate intensity exercise in adults with mgeffect of light vs. moderate intensity exercise on health outcomes. participants will be enrolled into the neurowell exercise program, which is geared toward individuals with neurological disorders or injuries and led by certified exercise physiologists (ceps) at the healthpartners neuroscience center. a total of 20 people with mg will be enrolled in this study and participate in a small group exercise program 3 times a week for 12 weeks. participants will be randomized into two exercise groups: 1) light intensity or 2) moderate intensity. we hypothesize that light and moderate intensity exercise will be feasible, acceptable, and tolerable in adults with mg and that individuals in the light intensity exercise group will be able to achieve the same improvement in health outcomes as the moderate intensity group.


Eligibility criteria:
inclusion criteria: * ability to provide and provision of signed and dated informed consent form. * age 18-80 * diagnosis of generalized mg. * on a stable mg prescription medication regimen for the last 3 months. exclusion criteria: * non-english speaking * regular exercise participation within the month prior to study enrollment or any outside exercise participation during the study intervention period. * significant cognitive impairment of any etiology that would impact study participation. * history of heart failure, chronic lung disease, angina or any other condition that causes unreasonable shortness of breath on exertion. * history of any serious neurological, psychiatric, or substance use disorders that would impact study participation. * women who are currently pregnant or planning to become pregnant during the study. * any other medical conditions that could affect their ability to participate in exercise for the study duration (as determined by study investigators). * active participation or past participation ≤3 months in any other interventional research study. * unwilling to participate in all study related activities.
safety and efficacy study of dutogliptin/phx1149t to treat type 2 diabetes mellitus

Conditions: Type 2 Diabetes Mellitus

Summary: a phase 3, randomized, double-blind, placebo-controlled, multi-center study to evaluate safety and efficacy of phx1149t as monotherapy in subjects with type 2 diabetes mellitus


Eligibility criteria:
inclusion criteria: * type 2 diabetes mellitus, drug naïve or willing to wash-out from existing oral therapy * bmi 25 to 48 kg/m2, inclusive * hba1c 7.0% - 10.0%, inclusive * age 18 to 75 years, inclusive exclusion criteria: * currently on 3 or more oral antidiabetic drugs or insulin. * type 1 diabetes mellitus

Keywords: dutogliptin phx1149 dpp4 inhibitor
efficacy of methotrexate in myasthenia gravis

Conditions: Myasthenia Gravis

Summary: myasthenia gravis is a rare neuromuscular disorder characterized by weakness and fatigability of ocular, bulbar, and extremity musculature. the specific aim of this study is to determine if oral methotrexate is an effective therapy for myasthenia gravis (mg) patients who are prednisone dependent. patients will be randomized to receive either methotrexate or placebo and those who are entered onto this trial will have symptoms and signs of the disease while on prednisone therapy. the hypothesis is that adding methotrexate therapy in these patients will improve the mg manifestations so that the prednisone dose can be reduced and clinical measures of mg severity will improve. funding source - fda oopd


Eligibility criteria:
inclusion criteria: * patients must have mgfa mg grades 2, 3, or 4 generalized myasthenia gravis, according to the mgfa classification system * elevated acetylcholine receptor antibody (achr-ab) titer. * patient's signs and symptoms should not be better explained by another disease process. * prednisone dose of at least 10 mg/day (or the equivalent in alternate days) and the subject must be on a stable dose of prednisone for 30 days prior to the screening visit. exclusion criteria: * a history of chronic degenerative, psychiatric, or neurologic disorder other than mg that can produce weakness or fatigue. * other major chronic or debilitating illnesses within six months prior to study entry. * female patients who are premenopausal and are: (a) pregnant on the basis of a serum pregnancy test, (b) breast-feeding, or (c) not using an effective method of double barrier (1 hormonal plus 1 barrier method or 2 simultaneous barrier methods) birth control (birth control pills, male condom, female condom, intrauterine device, norplant, tubal ligation, or other sterilization procedures). * altered levels of consciousness, dementia, or abnormal mental status. * evidence of thymoma on chest ct or mri. such a finding could require immediate thymectomy and would preclude entry into the study. * thymectomy in the previous three months. * patients who have been medicated with azathioprine, cyclosporine, cyclophosphamide, mycophenolate mofetil, ivig, or other immunosuppressive drugs within the last 60 days. * chest x-ray with evidence of tumor, infection, or interstitial lung disease. * clinical history of chronic or recurrent infections. * daily use of non-steroidal anti-inflammatory drugs (nsaids). * history of renal or hepatic insufficiency or liver enzymes greater than the upper limit of normal. * history of bone marrow hypoplasia, leucopenia, thrombocytopenia, significant anemia, clinical or laboratory evidence of immunodeficiency syndromes. * forced vital capacity (fvc) \<50% of predicted. * mg grade 1 (ocular only) or 5 (crisis, requiring ventilator). * prior use of methotrexate for any condition.

Keywords: myasthenia gravis
fomepizole dosing during continuous renal replacement therapy (crrt)

Conditions: Toxic Alcohol Poisoning

Summary: the project is a prospective observation study of patients with suspected or confirmed toxic alcohol poisoning treated with fomepizole and continuous renal replacement therapy (crrt)


Eligibility criteria:
inclusion criteria: * patients (over 18 year) with suspected or confirmed toxic alcohol poisoning treated with fomepizole and crrt. exclusion criteria: * patients who wish to withdraw from the study
intestinal transport of microbial metabolites in chronic kidney disease

Conditions: Chronic Kidney Disease

Summary: chronic kidney disease is associated with the accumulation of various metabolites, i.e., uremic retention solutes. evidence is mounting that the colonic microbiome contributes substantially to these uremic retention solutes. indoxyl sulfate and p-cresyl sulfate are among the most extensively studied gut microbial metabolites, and are associated with cardiovascular disease, chronic kidney disease progression and overall mortality. mechanisms governing their intestinal uptake and metabolism, however, are currently unknown. the investigators aim to explore these transport characteristics in depth. therefore, colonic biopsies will be sampled of patients with chronic kidney disease, analyzed and compared to available data of healthy controls. insights in the mechanisms controlling intestinal transport and metabolism of indoxyl sulfate and p-cresyl sulfate is certainly relevant as it might lead to novel therapeutic targets in the treatment of chronic kidney disease.


Eligibility criteria:
inclusion criteria: * age ≥ 18 and ≤ 85 years * chronic kidney disease ≤ stage iii (kdoqi), i.e., estimated glomerular filtration rate (mdrd) \< 60 ml/min/m² or need of dialysis therapy 27 * scheduled colonoscopy for diagnostic purposes * written informed consent exclusion criteria: * history of gastro-intestinal disease (e.g., inflammatory bowel disease) * history of colon surgery * recipient of a renal or other solid organ transplant * exposure to antibiotics or drug therapy with a known influence on intestinal transporters (e.g., p-gp) or enzymes during 2 weeks before colonoscopy
evaluation of the pharmacokinetics and safety of bay3427080 (nt-814) in post-menopausal women with vasomotor symptoms

Conditions: Post-menopausal Vasomotor Symptoms

Summary: this is a multi-center, double-blind, randomized, placebo-controlled multiple ascending dose study in post-menopausal women with vasomotor symptoms. single ascending doses of nt-814 will be investigated in 4 cohorts. each cohort will comprise of 20 subjects. subjects will be dosed for 14 days.


Eligibility criteria:
inclusion criteria: * post-menopausal female subjects experiencing frequent moderate to severe hot flashes.menopause will be defined as: * 12 months of spontaneous amenorrhea; * or at least 6 weeks' post-surgical bilateral oophorectomy with or without hysterectomy. exclusion criteria: * bmi \> 35kg/m2. * any active comorbid disease, ecg or laboratory result deemed by the investigator to be clinically significant and which could impact safety during study conduct or that could interfere with the study evaluation, procedures or completion. * use of prohibited medications defined in the protocol. * inability or unwillingness to comply with study procedures or requirements.

Keywords: hot flashes post-menopausal
reactions to reduced nicotine cigarettes in young adult low-frequency smokers

Conditions: Nicotine Dependence

Summary: the purpose of this study is to evaluate reactions to, and choices to self-administer, cigarette smoke with varying nicotine content among low-frequency, non-dependent adolescent/young adult smokers between the ages of 15-25 years.

participants will undergo three sessions in which their reactions to fixed doses of smoke from investigational cigarettes with three different nicotine contents (15.8 mg/gram of tobacco, 2.5 mg/g, and .4 mg/g) will be assessed. following the third fixed-dose session, participants will return to the lab to choose one of the cigarettes to self-administer.

Eligibility criteria:
inclusion criteria: * generally healthy * between the ages of 15-25 * use nicotine or tobacco products between 1-15 days/month for at least 6 months * smokes at least 5 cigarettes/month * no unstable or significant medical or psychiatric conditions * breath alcohol value=0.000 * able to provide contact information for two individuals who can corroborate smoking status exclusion criteria: * use of illegal drugs as measured by urine drug screen (excluding thc) * serious quit attempt in the past 3 months * plans to quit smoking in the next 2 months * current use of nicotine replacement therapy or other tobacco cessation products * inability to attend all required experimental sessions * blood pressure \>160/100 mmhg * pregnant, trying to become pregnant, or breastfeeding

Keywords: smoker young adult adolescent